Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631001 | 0.88 | NPC1 (0.52) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL28878462 | 0.85 | RAB9A (0.60) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL23951 | 0.82 | MAPT (0.59) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL29173072 | 0.81 | MAPT (0.58) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL28486325 | 0.81 | MAPT (0.58) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL29093271 | 0.81 | MAPT (0.58) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL154728 | 0.81 | NPC1 (0.50) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL14075117 | 0.81 | NPC1 (0.48) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL559645 | 0.80 | PRMT6 (0.45) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL27818006 | 0.80 | CYP1A2 (0.52) | NPC1RAB9AKMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0343307-A1 | 4-Piperidinealkanamine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1989-11-29 | — | — | EP | claimed |
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-115872985-B | 1,2,3, 4-Tetrahydroisoquinoline-thiophene derivative and preparation method thereof | 赣江中药创新中心 | 2025-01-14 | — | — | CN | disclosed |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-115926184-B | Fe-Mn mixed metal MOF, preparation and application thereof in thiol catalytic oxidation | 山西师范大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-112449637-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-110647010-B | Resin composition, dry film, method for producing dry film, resist film, substrate, and method for producing plating molded article | 东京应化工业株式会社 | 2024-02-09 | — | — | CN | disclosed |
| EP-3104426-B1 | ORGANIC TRANSISTOR, COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL FOR NON-LUMINESCENT ORGANIC SEMICONDUCTOR DEVICE, MATERIAL FOR ORGANIC TRANSISTOR, COATING SOLUTION FOR NON-LUMINESCENT ORGANIC SEMICONDUCTOR DEVICE, AND ORGANIC SEMICONDUCTOR FILM FOR NON-LUMINESCENT ORGANIC SEMICONDUCTOR DEVICE | FUJIFILM CORP (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-6162930-A | Anti-mitotic agents which inhibit tubulin polymerization | BAYLOR UNIVERSITY (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5886025-A | METHOXY AND ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES | BAYLOR UNIVERSITY (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
| EP-0427404-B1 | Anthanthrone derivatives | ZENECA LTD (GB) | 1994-05-25 | — | — | EP | disclosed |
| US-5099071-A | Charge generating compounds for electrophotographic devices | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| EP-0427404-A2 | Anthanthrone derivatives | ZENECA LIMITED (GB) | 1991-05-15 | — | — | EP | disclosed |
| EP-0343307-A1 | 4-Piperidinealkanamine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1989-11-29 | — | — | EP | disclosed |
| US-4300942-A | N-(Substituted carbonyl) derivatives of N-phos-phinylmethylglycinates and the herbicidal use thereof | MONSANTO COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4251258-A | N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof | MONSANTO COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | SORD, HEXD, SNRPD1 | NPC1 2418/4885RAB9A 2314/4885KMT2A 2327/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | NPC1 2835/4885RAB9A 2097/4885KMT2A 1765/4885 |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | NPC1 308/4885RAB9A 2139/4885KMT2A 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.